OTCMKTS:ELOXD Eloxx Pharmaceuticals (ELOXD) Stock Price, News & Analysis $6.20 0.00 (0.00%) As of 10/15/2026 Add Compare Share Share Stock Analysis Stock AnalysisChartFinancialsNews and TrendsSEC Filings About Eloxx Pharmaceuticals Stock (OTCMKTS:ELOXD) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Eloxx Pharmaceuticals alerts:Sign Up Key Stats Today's Range$6.20▼$6.2050-Day Range$6.20▼$6.2052-Week Range$0.00▼$10.00VolumeN/AAverage Volume3,320 shsMarket Capitalization$2.86 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Eloxx Pharmaceuticals, Inc. was a clinical-stage biopharmaceutical company focused on developing therapies for genetic diseases caused by nonsense mutations. Its research centered on ribosome modulation, an approach intended to encourage cells to produce functional proteins from genes containing premature stop signals. The company’s lead investigational product was ELX-02, a synthetic aminoglycoside designed to promote read-through of nonsense mutations. Eloxx evaluated ELX-02 in rare disease programs, including cystinosis and cystic fibrosis, and pursued additional potential applications in other genetic disorders. These products were investigational and had not been established as approved commercial therapies. Eloxx conducted development activities through clinical and regulatory programs in the United States and other international markets. The company subsequently faced significant financial and operational challenges, and publicly available information about its ongoing operations, leadership, and active product development is limited. Eloxx Pharmaceuticals is associated with the over-the-counter symbol ELOXD.AI Generated. May Contain Errors. Read More Receive ELOXD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Eloxx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ELOXD Stock News HeadlinesCantor Fitzgerald initiates coverage of Eloxx Pharmaceuticals at overweightOctober 15 at 5:26 PM | msn.comLeerink Partners Initiates Eloxx Pharmaceuticals With Outperform Rating, $32 PTSeptember 18, 2026 | marketscreener.comMDid you grab your copy yet?Bill Poulos's Top 10 Stocks to Buy This Quarter report is still available free, but not for long. Every quarter he swaps in a brand-new list, and once the new edition launches, this one disappears. Investors who want a current snapshot of his picks should grab a copy now and save it before the switch happens.October 16 at 1:00 AM | Profits Run (Ad)Eloxx Pharmaceuticals, Inc.: Eloxx Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business UpdateAugust 12, 2026 | finanznachrichten.deEloxx Pharmaceuticals, Inc. Announces Pricing of $66.0 Million Public Offering and Uplisting to NasdaqJune 8, 2026 | prnewswire.comEloxx Pharmaceuticals Inc.May 24, 2026 | barrons.comEloxx Pharmaceuticals Inc. (ELOX) SEC FilingsMay 21, 2026 | nasdaq.comEloxx Pharmaceuticals Delays Form 10-Q FilingAugust 15, 2025 | msn.comSee More Headlines ELOXD Stock Analysis - Frequently Asked Questions How have ELOXD shares performed this year? Eloxx Pharmaceuticals' stock was trading at $0.0011 at the beginning of 2026. Since then, ELOXD stock has increased by 563,536.4% and is now trading at $6.20. How were Eloxx Pharmaceuticals' earnings last quarter? Eloxx Pharmaceuticals, Inc. (OTCMKTS:ELOXD) posted its earnings results on Monday, April, 3rd. The company reported ($32.12) EPS for the quarter, topping analysts' consensus estimates of ($32.67) by $0.55. When did Eloxx Pharmaceuticals' stock split? Shares of Eloxx Pharmaceuticals reverse split on Monday, June 1st 2026.The 1-11 reverse split was announced on Monday, June 1st 2026. The number of shares owned by shareholders was adjusted after the market closes on Monday, June 1st 2026. An investor that had 100 shares of stock prior to the reverse split would have 9 shares after the split. How do I buy shares of Eloxx Pharmaceuticals? Shares of ELOXD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Eloxx Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Eloxx Pharmaceuticals investors own include Tesla (TSLA), Boeing (BA), Moderna (MRNA), Novavax (NVAX), Pfizer (PFE), Aldeyra Therapeutics (ALDX) and iBio (IBIO). Company Calendar Last Earnings4/03/2023Today10/16/2026Next Earnings (Estimated)11/11/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolOTCMKTS:ELOXD Previous SymbolNASDAQ:ELOX CIK1035354 Webwww.eloxxpharma.com Phone(781) 577-5300Fax908-864-4440Employees10Year Founded2013Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio0.53 Quick Ratio0.53 Sales & Book Value Annual Sales$6.36 million Price / Sales0.45 Cash FlowN/A Price / Cash FlowN/A Book Value($85.17) per share Price / Book-0.07Miscellaneous Outstanding Shares461,000Free Float342,000Market Cap$2.86 million OptionableNot Optionable Beta-1,932.72 Social Links 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (OTCMKTS:ELOXD) was last updated on 10/15/2026 by MarketBeat.com Staff. From Our PartnersElon Musk’s 4th Wealth Window Set to Open by October 30Jeff Brown, the analyst who flagged Bitcoin, Tesla, and Nvidia early, is tracking Elon Musk's next move. He po...Brownstone Research | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leadin...Weiss Ratings | SponsoredTrump’s issues shocking Executive Order on U.S. DollarThree days into his second term, President Trump signed Executive Order 14178 a move the press barely covered....Banyan Hill Publishing | SponsoredINSANE DRONE FOOTAGENew drone footage shows a mysterious factory rising at one of Elon Musk's most secure facilities, cleared and ...Paradigm Press | SponsoredSpaceX minted 4400 millionaires in a single daySpaceX minted 4,400 millionaires in a single day, and Tesla has turned more than 5,000 employees into milliona...Behind the Markets | SponsoredA new income category is drawing serious money - here's whyForbes recently called a new category of exchange-traded income funds a 'golden era,' and Bloomberg noted the ...Investors Alley | SponsoredUndiscovered Sub-$1 Gold-Silver Royalty Stock Takes FlightA small-cap gold and silver royalty company is generating record revenue from producing mines, yet shares stil...Digest Publishing | SponsoredDid you grab your copy yet?Bill Poulos's Top 10 Stocks to Buy This Quarter report is still available free, but not for long. Every quarte...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eloxx Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eloxx Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ELOXD Stock Alerts